ORIC Pharmaceuticals
ORIC Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company developing therapies to overcome resistance mechanisms in cancer. The company discovers and advances small molecule oncology candidates targeting resistance pathways, including ORIC-114 for EGFR/HER2-mutated non-small cell lung cancer and ORIC-944 for prostate cancer. Main revenue drivers currently comprise investment capital financing, strategic pharmaceutical research grants, and milestone licensing payments as clinical trials progress. ORIC Pharmaceuticals targets medical oncologists, clinical trial research centers, biopharmaceutical collaborators, and cancer patients across North America. The company holds an innovative position in precision oncology and drug resistance therapeutics. Headquartered in South San Francisco, California, ORIC Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in ORIC Pharmaceuticals.
- Legal name
- ORIC Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding ORIC Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.79 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)